Vitamin B12

• Correcting documented B12 deficiency
• Pernicious anemia (autoimmune, lifelong)
• Strict vegan and long-term vegetarian diets
• Older adults with atrophic gastritis or low stomach acid
• Malabsorption (Crohn's, celiac, gastric or ileal surgery)
• Deficiency linked to long-term metformin or acid-suppressing drugs
• Restoring energy and cognition when deficiency is the documented cause

Vitamin B12 (cobalamin) is unique among vitamins in containing a metal atom, cobalt, at the center of its corrinoid ring structure. This unusual chemistry reflects an unusual biological origin: B12 is the only vitamin synthesized exclusively by microorganisms (bacteria and archaea), with no plant or animal capable of endogenous synthesis. Humans obtain B12 either from animal foods (which accumulate microbial B12 through dietary and gut bacterial sources) or from supplementation. The molecular complexity is matched by elaborate absorption biology: dietary B12 binds to haptocorrin in saliva, is released by gastric acid and pepsin in the stomach, transfers to intrinsic factor (IF) secreted by gastric parietal cells, traverses the small intestine bound to IF, and is absorbed via specific IF receptors (cubilin-amnionless complex) in the terminal ileum. This multi-step absorption pathway has multiple failure points: achlorhydria from PPI use or aging disrupts initial release; autoimmune destruction of parietal cells eliminates intrinsic factor production (pernicious anemia); ileal disease or resection eliminates the absorption site; metformin disrupts the calcium-dependent ileal absorption step. The result is that B12 deficiency is paradoxically common despite typically adequate dietary intake, particularly among older adults, PPI users, metformin users, post-bariatric-surgery patients, and people with intestinal disease. The two B12-dependent enzymatic reactions in human physiology are mechanistically distinct and clinically central. Methylcobalamin (the methylated active form) serves as cofactor for methionine synthase in the cytoplasm, converting homocysteine to methionine and 5-methyltetrahydrofolate to tetrahydrofolate, the central reaction linking B12 status, folate metabolism, and one-carbon methylation chemistry. Adenosylcobalamin (the adenosylated active form) serves as cofactor for methylmalonyl-CoA mutase in mitochondria, converting methylmalonyl-CoA to succinyl-CoA in the propionate metabolism pathway. B12 deficiency produces accumulation of both homocysteine (elevated total plasma homocysteine) and methylmalonic acid (elevated serum MMA), the two most sensitive deficiency markers. Both elevations contribute to clinical manifestations: homocysteine elevation drives the megaloblastic anemia (through DNA synthesis disruption shared with folate deficiency) and contributes to cardiovascular and neurologic effects; MMA elevation specifically contributes to the demyelinating neuropathy and cognitive manifestations distinctive to B12 deficiency (and not produced by folate deficiency despite the overlapping megaloblastic anemia). The clinical distinction matters enormously: high-dose folate supplementation can correct the anemia of B12 deficiency while allowing the neurologic damage to progress, the historical concern that drove cautious folic acid fortification policy and remains relevant in modern B12-folate clinical management.

B12 dosing varies enormously based on indication. For routine maintenance in users at risk of deficiency (vegans, older adults, long-term metformin or PPI users), 25-100mcg daily oral or 1000mcg weekly is generally adequate to prevent deficiency. The unusual feature of B12 dosing is that high-dose oral cyanocobalamin (1000-2000mcg daily) can effectively treat even pernicious anemia, even without intrinsic factor, because approximately 1% of oral B12 is absorbed passively through diffusion. At 1000mcg oral daily, the passive absorption alone (~10mcg) substantially exceeds physiological needs (RDA 2.4mcg). This finding (consolidated by Bolaman 2003 and Andrès 2004) revolutionized pernicious anemia treatment, shifting practice from universal monthly IM injection to oral high-dose protocols for most stable patients. IM injection remains preferred for severe deficiency with neurologic manifestations (where rapid repletion is desired), absorption pathway disruption beyond passive uptake range, and patients with adherence concerns. Pediatric dosing is per pediatric protocol. Pregnancy requires only modestly elevated intake (2.6-2.8mcg RDA) but vegan pregnancies warrant higher supplementation (100mcg+ daily). No Upper Limit has been established for B12; even high doses (1000mcg+ daily) are well-tolerated in most users. Sublingual products are reasonable for users with absorption concerns or preference; oral high-dose is generally adequate for most users including those with mild absorption issues. The diagnostic framework is important: serum B12 alone is insensitive (subclinical deficiency can occur with apparently normal serum levels); methylmalonic acid (MMA) and homocysteine are more sensitive functional markers; holotranscobalamin is an emerging more-sensitive marker.

RDA adult

2.4mcg/day

RDA pregnancy / lactation

2.6-2.8mcg/day

Vegan supplementation

25-100mcg/day OR 1000mcg/week

Routine prevention (older, PPI, metformin)

25-500mcg/day

Pernicious anemia (oral)

1000-2000mcg/day

Pernicious anemia (IM cyanocobalamin)

1000mcg monthly

Pernicious anemia (IM hydroxocobalamin)

1000mcg every 2-3 months

Upper Limit

None established

• Cyanocobalamin (Synthetic Standard)

  Rating: gold

  The most-studied and most-used B12 form in clinical trials, multivitamins, and pharmaceutical preparations. Cyanide group is cleaved in vivo to release active cobalamin; clinical effects equivalent to other forms in most contexts. Cheapest form; stable in formulations. The "B12 toxicity from cyanide" framing in functional medicine substantially exceeds the trace cyanide content of clinical doses.

• Methylcobalamin (Active Methylated Form)

  Rating: gold

  Active methylated form that directly serves as methionine synthase cofactor without requiring conversion. Popular in modern consumer and functional medicine contexts; particularly preferred for neurologic indications and methylation-pathway protocols. Comparable absorption to cyanocobalamin; clinical superiority is suggestive rather than definitive at standard doses.

• Hydroxocobalamin (Clinical IM)

  Rating: gold

  Hydroxylated form widely used in clinical IM injection for pernicious anemia treatment in Europe and increasingly elsewhere. Longer plasma half-life than cyanocobalamin enables less frequent injection (every 2-3 months in stable patients vs monthly for cyanocobalamin IM). Also used as IV cyanide antidote (Cyanokit) at much higher doses.

• Adenosylcobalamin (Mitochondrial Active Form)

  Rating: good

  Active adenosylated form that directly serves as methylmalonyl-CoA mutase cofactor. Marketed in functional medicine for mitochondrial and energy metabolism support; mechanistically reasonable but comparative clinical evidence is limited. Often combined with methylcobalamin for "complete active B12" formulations.

• Sublingual B12 (Methyl- or Cyano-cobalamin)

  Rating: good

  Sublingual tablets or lozenges designed for buccal/sublingual absorption bypassing gastric absorption pathway. Mechanistically reasonable for users with intrinsic factor or ileal absorption issues; clinical superiority over oral tablets at equivalent dose is debated. Comparable absorption studies generally show modest sublingual advantage; clinical outcomes generally similar.

• IM Injection (Cyanocobalamin or Hydroxocobalamin)

  Rating: gold

  Intramuscular injection bypasses all absorption pathway issues. Historical standard for pernicious anemia treatment; now largely supplanted by high-dose oral protocols for stable patients but retained for severe deficiency, severe neurologic manifestations, and absorption pathway disruption. Cyanocobalamin in US (monthly); hydroxocobalamin elsewhere (every 2-3 months).

• B12 Nasal Spray (Nascobal)

  Rating: good

  Prescription intranasal cyanocobalamin formulation. Bypasses gastric absorption pathway through nasal mucosa absorption. Reasonable alternative for users with absorption issues who prefer to avoid injection. Higher cost than oral high-dose alternatives.

• B12 in Multivitamins

  Rating: good

  Most multivitamins include B12 at 2-100mcg per serving. Adequate for general supplementation in most healthy users; not adequate for established deficiency treatment. Specific high-dose B12 products needed for clinical deficiency repletion.

• Pernicious anemia (autoimmune)

  Strength of evidence for this group: strong

  Classical deficiency syndrome with established treatment (IM cyanocobalamin monthly, hydroxocobalamin quarterly, or high-dose oral cyanocobalamin 1000-2000mcg daily). Lifelong treatment required. Specialist coordination through hematology or primary care depending on severity. Bolaman 2003 and Andrès 2004 support high-dose oral as non-inferior to IM in stable patients.

• Vegan and strict vegetarian diet

  Strength of evidence for this group: strong

  B12 is essentially absent from plant foods (microbial-source contamination of fermented foods provides unreliable doses). Vegan diet WITHOUT B12 supplementation produces deficiency over months to years. Modest supplementation (25-100mcg daily or 1000mcg weekly) prevents deficiency. Among the most clearly indicated supplementation use cases in modern nutrition.

• Older adults (gastric atrophy, marginal absorption)

  Strength of evidence for this group: strong

  Up to 30% of adults over 60 have reduced gastric acid (atrophic gastritis) producing impaired B12 release from food. Sub-clinical deficiency is common even with apparently adequate dietary intake. IOM and other guidance suggests routine supplementation or fortified food consumption after age 50. The supplementation form (cyanocobalamin or methylcobalamin) bypasses the food-release issue.

• Long-term metformin users (diabetes)

  Strength of evidence for this group: modest

  Reynolds 2010 and subsequent work establish clinically meaningful B12 depletion in 10-30% of long-term metformin users. Mechanism involves calcium-dependent ileal absorption disruption. Modern endocrinology guidance increasingly includes B12 monitoring and supplementation in long-term metformin patients.

• Long-term PPI / H2 blocker users

  Strength of evidence for this group: modest

  Reduced gastric acid impairs B12 release from food. Long-term PPI use (>2 years) is associated with B12 status decline. Routine supplementation in long-term acid-suppression therapy is reasonable; the form (supplements bypass the food-release issue) addresses the mechanism appropriately.

• Post-bariatric surgery

  Strength of evidence for this group: strong

  Roux-en-Y gastric bypass and other bariatric procedures fundamentally disrupt B12 absorption pathway (reduced gastric acid, reduced intrinsic factor, anatomic bypass of absorption sites). Lifelong B12 supplementation is established clinical practice. Specialist coordination through bariatric medicine.

• Inflammatory bowel disease (terminal ileal involvement)

  Strength of evidence for this group: strong

  Crohn's disease with terminal ileal involvement, ileal resection, and ulcerative colitis with extensive colonic disease can produce B12 malabsorption. Specialist coordination through gastroenterology; IM injection often preferred over oral due to absorption disruption.

• Pregnancy and lactation (vegan or marginal status)

  Strength of evidence for this group: strong

  Maternal B12 deficiency during pregnancy can produce severe and irreversible neurologic damage in nursing infants. Particularly critical for vegan pregnancies. Standard prenatal vitamin B12 content (2.6-2.8mcg) is adequate in most pregnancies; higher doses (100mcg+) reasonable for vegan or marginal status. Among the clearest critical-window B12 indications.

• Cognitive impairment in older adults

  Strength of evidence for this group: cautious

  Stabler 2004 and subsequent work established associations between B12 deficiency and cognitive decline. Supplementation in deficient older adults can improve cognitive function; supplementation in B12-replete older adults does not appear to improve cognition. Assess B12 status (serum B12, MMA) before targeted supplementation.

• Asymptomatic adults with normal diet

  Strength of evidence for this group: cautious

  B12 deficiency is uncommon in non-vegetarian adults under 60 with normal absorption. Routine multivitamin B12 (typically 2-25mcg) is adequate; targeted high-dose B12 supplementation outside specific indication does not provide benefit for most healthy users.

• Folate / Methylfolate

  Interaction: synergy

  The signature B12 pairing. Both B12 and folate participate in methionine synthase reaction; deficiency in either produces megaloblastic anemia. Critical clinical concern: high-dose folate can mask the anemia of B12 deficiency while allowing neurologic damage to progress. Modern fortification policy and combined B-complex supplements address this through routine B12 inclusion alongside folate.

• B-Complex Vitamins

  Interaction: synergy

  B12 is typically included in B-complex formulations alongside thiamine, riboflavin, niacin, pantothenic acid, B6, biotin, and folate. Mechanistically integrated through one-carbon metabolism and energy pathways. Reasonable comprehensive B vitamin supplementation; most users benefit from B-complex over isolated B12 unless specifically targeting B12 deficiency.

• Iron

  Interaction: synergy

  Megaloblastic anemia (B12/folate deficiency) and iron deficiency anemia have different mechanisms but may coexist. Iron deficiency masks the megaloblastic features of B12 deficiency in blood smear; combined deficiency is common in vegans and reproductive-age women. Often supplemented together in deficiency repletion.

• Metformin

  Interaction: caution

  Long-term metformin use depletes B12 in 10-30% of patients. Not a contraindication but warrants routine B12 monitoring and reasonable prophylactic supplementation (500-1000mcg daily) during long-term metformin therapy.

• Proton Pump Inhibitors / H2 Blockers

  Interaction: caution

  Reduced gastric acid impairs B12 release from food. Long-term acid suppression warrants B12 monitoring and supplementation; the supplement form bypasses the food-release issue.

• Nitrous Oxide (Anesthesia, Recreational)

  Interaction: caution

  Nitrous oxide irreversibly oxidizes cobalt in cobalamin, inactivating B12. Single anesthesia exposure produces transient B12 inactivation; chronic recreational nitrous oxide use produces clinically severe B12 deficiency with neurologic manifestations. Recreational nitrous use is increasing concern; substantial neurologic damage documented.

• H. pylori Infection

  Interaction: caution

  Chronic H. pylori infection contributes to atrophic gastritis and B12 absorption disruption. Treatment of H. pylori may partially restore absorption capacity.

• Cyanide-Containing Foods (Smoking, Bitter Almonds)

  Interaction: neutral

  Cyanocobalamin contains small amount of cyanide which is harmless in normal users but can theoretically contribute to cyanide load in heavy smokers or other cyanide-exposed users. Hydroxocobalamin or methylcobalamin reasonable for users concerned about cyanide load; clinical relevance is modest at typical supplement doses.

• Chloramphenicol (Antibiotic)

  Interaction: caution

  Chloramphenicol may interfere with B12 response in deficiency treatment. Coordinate with prescribing physician if both required.

Look for: specific B12 form disclosed clearly (cyanocobalamin, methylcobalamin, hydroxocobalamin, adenosylcobalamin); explicit mcg content per serving; appropriate dose for indication (25-100mcg for routine; 1000mcg+ for deficiency); USP or NSF third-party verification for clinical-grade products; sublingual or oral formulation per preference; reasonable price (B12 is genuinely inexpensive at commodity pricing). Avoid: very low dose products (<2mcg) for users with deficiency indications; proprietary "energy" or "nerve health" blends obscuring B12 dose; products marketed with cyanide-fear positioning to justify premium methylcobalamin pricing; products from manufacturers without third-party testing disclosure; very high-dose products (>5000mcg) without specific indication.

B12's story begins as the answer to pernicious anemia, historically a uniformly fatal disease producing megaloblastic anemia, demyelinating neuropathy, and progressive neurologic deterioration over months to years. The therapeutic breakthrough came in the 1920s with George Whipple's observation that raw liver feeding produced dramatic remission in anemic dogs (later humans). George Minot and William Murphy at Harvard developed liver therapy for pernicious anemia in humans, initially requiring patients to eat raw or barely-cooked liver in substantial quantities, an unpleasant but life-saving therapy. The 1934 Nobel Prize in Physiology or Medicine recognized this work, though the active ingredient remained unknown. William Castle at Harvard Medical School demonstrated in 1929 that gastric secretions contained an "intrinsic factor" essential for the antianemic effect of liver, connecting the gastric atrophy commonly observed in pernicious anemia patients to the absorption defect. The "extrinsic factor" (the actual vitamin) remained chemically unknown for two more decades. The race to isolate the compound culminated in 1948 with essentially simultaneous isolation by Edward Rickes at Merck and Lester Smith at Glaxo, both crystallizing the deep red cobalt-containing compound. The name "vitamin B12" reflected its position in the B vitamin enumeration; the technical name "cobalamin" emerged later. Dorothy Hodgkin's structural characterization through X-ray crystallography (Nature 1956) was a tour de force of mid-20th century structural chemistry, establishing the corrinoid ring structure with central cobalt atom that distinguishes B12 from all other vitamins. Hodgkin received the 1964 Nobel Prize in Chemistry, partly for this work. Robert Schilling's development of the radioactive B12 absorption test (1953) provided diagnostic tool that dominated pernicious anemia diagnosis for decades; modern practice has largely replaced Schilling testing with anti-intrinsic-factor antibody assays and methylmalonic acid measurement. The modern era has seen substantial expansion of recognized B12 deficiency causes beyond classical pernicious anemia. Vegan diet recognition (mid-20th century), older adult atrophic gastritis (later 20th century), metformin depletion (Reynolds 2010), PPI association (multiple studies through 2000s-2010s), and post-bariatric surgery deficiency (post-1990s with bariatric surgery expansion) have all become important clinical contexts. The Bolaman 2003 and Andrès 2004 work on high-dose oral B12 substantially shifted clinical practice from universal IM injection to oral protocols for most stable patients, a substantial practice evolution. The Allen 2009 global B12 deficiency assessment established that B12 deficiency is far more common globally than typically recognized, particularly in vegetarian/vegan populations and developing-country populations with limited animal source food access. Public health responses have included food fortification (breakfast cereals, plant milks) and targeted supplementation programs. The modern consumer functional medicine B12 era has emphasized methylcobalamin (the active methylated form) over cyanocobalamin (the synthetic standard), partly based on mechanistic preference for active forms and partly based on the methylation-pathway emphasis in functional medicine. The clinical superiority of methylcobalamin over cyanocobalamin at equivalent doses remains debated; most rigorous comparison studies show equivalent clinical outcomes. The recreational nitrous oxide emergence (particularly through "whippet" canister abuse) has produced a growing clinical population with severe B12 deficiency through nitrous oxide-mediated cobalamin inactivation. The neurologic consequences (myelopathy, peripheral neuropathy, cognitive decline) can be severe and partially irreversible, generating substantial recent clinical literature.

1. 1920sWhipple, Minot, Murphy develop liver therapy for pernicious anemia
2. 1929Castle demonstrates intrinsic factor
3. 1934Nobel Prize for liver therapy (Whipple, Minot, Murphy)
4. 1948Rickes (Merck) and Smith (Glaxo) isolate crystalline B12
5. 1953Schilling absorption test developed
6. 1956Hodgkin X-ray crystallography structure (Nobel Chemistry 1964)
7. 1960s-70sVegan B12 deficiency recognition
8. 1990sPost-bariatric surgery B12 deficiency emerges with surgical expansion
9. 2003-2004Bolaman and Andrès establish oral high-dose paradigm
10. 2009Allen global B12 deficiency prevalence
11. 2010Reynolds metformin B12 depletion
12. 2013Stabler NEJM clinical review consolidates modern practice
13. 2020sRecreational nitrous oxide B12 deficiency emerges as clinical concern

• Whether methylcobalamin produces clinically distinguishable outcomes versus cyanocobalamin at equivalent doses, most evidence suggests equivalent effects with possible subtle differences in tissue-specific delivery.
• Whether subclinical B12 deficiency (elevated MMA, normal serum B12) in older adults warrants routine supplementation as preventive measure or only when functional consequences are documented.
• Whether holotranscobalamin should replace serum B12 as primary diagnostic marker, emerging research suggests improved sensitivity but routine availability is limited.
• Whether the cognitive decline association with B12 deficiency produces measurable benefits from supplementation in cognitively normal but B12-marginal older adults.
• Whether MTHFR polymorphism (independently relevant to folate metabolism) modulates individual B12 requirements through methylation pathway interactions.
• How best to manage long-term recreational nitrous oxide users with severe B12 deficiency, clinical experience is growing but evidence-based protocols are emerging.
• Whether the metformin B12 depletion mechanism (calcium-dependent ileal absorption) can be addressed through calcium co-supplementation as alternative to B12 supplementation.
• Whether B12 has applications in tinnitus, restless legs syndrome, or other specific neurological conditions where preliminary evidence exists.

Universally available globally as dietary supplement, food fortification, pharmaceutical product, and prescription IM injection. Legal under DSHEA in the United States and equivalent regulations globally. Not on WADA prohibited list. Pharmaceutical B12 (cyanocobalamin, hydroxocobalamin) is widely available; prescription IM injections are standard for pernicious anemia management. Major retail brands include Nature's Bounty, NOW Foods, Thorne, Pure Encapsulations, Solgar, Jarrow Formulas, and most multivitamin manufacturers. Methylcobalamin from Source Naturals, Thorne, Designs for Health, and others is widely available. Sublingual products are common consumer format. Nascobal (intranasal cyanocobalamin) is a prescription specialty product. Food fortification (breakfast cereals, plant milks) provides substantial population-level B12 exposure. Production through bacterial fermentation (typically Propionibacterium or Pseudomonas species) is well-established at commodity pricing; supply is broadly accessible.

Status current as of July 2026. Regulatory positions change, sometimes quickly.

Status

Water-soluble essential vitamin

Unique feature

Only vitamin containing a metal atom (cobalt)

Endogenous synthesis

None, exclusively microbial

RDA adult

2.4mcg/day

RDA pregnancy / lactation

2.6-2.8mcg/day

Upper Limit

None established

What follows is unfinished work on our side, not a finding about Vitamin B12. A short entry is not a safe entry.

• Cost and market. We have not documented what it sells for or who sells it.
• Supply chain. We have not mapped where it is made.
• Who uses it. We have not documented the user groups.
• What could change. No forward-looking summary yet.
• How it compares. We have not set it against the alternatives.
• Children and teenagers. We have not checked what is known about younger people.
• Where we land. We have not taken a position on this yet.